The in Vitro and in Vivo Anti-Cancer Potential of Mycobacterium Cell Wall Fraction (MCWF) Against Canine Transitional Cell Carcinoma of the Urinary Bladder
| Autor: | Aleksandar Masic, Chad M Johannes, C Mario Filion, Lucas Rodrigues |
|---|---|
| Přispěvatelé: | Institut Armand Frappier (INRS-IAF), Réseau International des Instituts Pasteur (RIIP)-Institut National de la Recherche Scientifique [Québec] (INRS), Estima Veterinary Hospital, Iowa State University (ISU), Educons University, NovaVive Inc., Institut National de la Recherche Scientifique [Québec] (INRS)-Réseau International des Instituts Pasteur (RIIP) |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Canine Transitional Cell Carcinoma
Palliative care 040301 veterinary sciences [SDV]Life Sciences [q-bio] Veterinary medicine urologic and male genital diseases 0403 veterinary science 03 medical and health sciences 0302 clinical medicine In vivo SF600-1100 medicine Trigone of urinary bladder canine tcc immunomodulatory Urinary bladder General Veterinary business.industry Cancer 04 agricultural and veterinary sciences mcwf medicine.disease female genital diseases and pregnancy complications 3. Good health medicine.anatomical_structure Transitional cell carcinoma 030220 oncology & carcinogenesis Cancer cell Cancer research business |
| Zdroj: | Acta Veterinaria, Vol 67, Iss 4, Pp 477-494 (2017) Acta veterinaria Acta veterinaria, Faculty of Veterinary Medicine Belgrade, 2017, 67, 4, pp.477-494. ⟨10.1515/acve-2017-0039⟩ |
| ISSN: | 1820-7448 0567-8315 |
| Popis: | Transitional cell carcinoma (TCC), is the most common form of urinary bladder cancer in dogs and represents 2% of all reported canine cancers. Canine TCC is usually a high-grade invasive cancer and problems associated with TCC include urinary tract obstruction and distant metastases in more than 50% of affected dogs. TCC is most commonly located in the trigone region of the bladder precluding complete surgical resection. Current treatment options for TCC in dogs include medical therapy, surgery or radiation. Mycobacterium Cell Wall Fraction (MCWF) is a biological immunomodulator derived from non-pathogenic Mycobacterium phlei. MCWF possesses a potential in multiple veterinary areas such as anticancer therapy, palliative care and treatment of infectious diseases in both small and large animals. MCWF is considered a bifunctional anti-cancer agent that induces apoptosis of cancer cells and stimulates cytokine and chemokines synthesis by cells of the immune system. Here we report the results from in vitro and in vivo studies that could suggest use of MCWF as an additional treatment option for TCC in dogs. Particularly, we demonstrated that MCWF induces a concentration dependent inhibition of proliferation of K9TCC cells which was associated with the induction of apoptosis as measured by the proteolytic activation of caspase-3 and the degradation of PARP. Furthermore, we demonstrated the safety and potential for in vivo MCWF treatment efficacy in dogs bearing stage T2 TCC by reducing clinical signs, and improving the quality of life in dogs with TCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|